{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:23:45Z","timestamp":1793391825306,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006520","name":"Edwards Lifesciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006520","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40258-025-01012-4","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T17:20:07Z","timestamp":1762536007000},"page":"365-378","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cost-Utility Analysis of TAVI Versus Surgery in Low-Risk Patients with Severe Aortic Stenosis in the UK"],"prefix":"10.1007","volume":"24","author":[{"given":"Nick","family":"Curzen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6728-451X","authenticated-orcid":false,"given":"Pascal","family":"Candolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"MacCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clinton T.","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Aetesam-Ur-Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Bromilow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Sellitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Blackman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"1012_CR1","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1161\/CIRCRESAHA.121.318040","volume":"128","author":"MT Boskovski","year":"2021","unstructured":"Boskovski MT, Gleason TG. Current therapeutic options in aortic stenosis. Circ Res. 2021;128:1398\u2013417.","journal-title":"Circ Res"},{"key":"1012_CR2","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.acvd.2012.01.005","volume":"105","author":"A Cribier","year":"2012","unstructured":"Cribier A. Development of transcatheter aortic valve implantation (TAVI): a 20-year odyssey. Arch Cardiovasc Dis. 2012;105:146\u201352.","journal-title":"Arch Cardiovasc Dis"},{"key":"1012_CR3","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/ejcts\/ezab389","volume":"60","author":"A Vahanian","year":"2021","unstructured":"Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC\/EACTS guidelines for the management of valvular heart disease. Eur J Cardiothorac Surg. 2021;60:727\u2013800.","journal-title":"Eur J Cardiothorac Surg"},{"key":"1012_CR4","doi-asserted-by":"crossref","unstructured":"Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin 3rd JP, Gentile F, et al. 2020 ACC\/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation 2021;143:e35\u201371 [Erratum in: Circulation 2021;143:e228. Erratum in: Circulation 2021;143:e784].","DOI":"10.1161\/CIR.0000000000000932"},{"key":"1012_CR5","unstructured":"National Institute of Healthcare Excellence (NICE). Heart valve disease presenting in adults: investigation and management. NICE guideline 2021 [NG208]. https:\/\/www.nice.org.uk\/guidance\/ng208\/documents\/html-content-2. Accessed 1 Nov 2025."},{"key":"1012_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2020-001547","volume":"8","author":"N Ali","year":"2021","unstructured":"Ali N, Faour A, Rawlins J, Dawkins S, Appleby CE, MacCarthy P, et al. \u2018Valve for Life\u2019: tackling the deficit in transcatheter treatment of heart valve disease in the UK. Open Heart. 2021;8:e001547.","journal-title":"Open Heart"},{"key":"1012_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2021-001783","volume":"9","author":"GA Strange","year":"2022","unstructured":"Strange GA, Stewart S, Curzen N, Ray S, Kendall S, Braidley P, et al. Uncovering the treatable burden of severe aortic stenosis in the UK. Open Heart. 2022;9:e001783.","journal-title":"Open Heart"},{"key":"1012_CR8","unstructured":"NHS England. Transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) for symptomatic, severe aortic stenosis (adults) to support elective performance. http:\/\/www.england.nhs.uk\/publication\/tavi-and-savr-position-statement\/. Accessed 1 Nov 2025."},{"issue":"5","key":"1012_CR9","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s10198-024-01739-2","volume":"26","author":"DJ Blackman","year":"2024","unstructured":"Blackman DJ, Ryschon AM, Barnett S, Garner AM, Forrest JK, Reardon MR, et al. Cost-effectiveness of TAVI in the United Kingdom: a long-term analysis based on 4-year data from the Evolut Low Risk Trial. Eur J Health Econ. 2024;26(5):745\u201355.","journal-title":"Eur J Health Econ"},{"key":"1012_CR10","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.jval.2021.10.003","volume":"25","author":"M Gilard","year":"2022","unstructured":"Gilard M, Eltchaninoff H, Iung B, Lef\u00e8vre T, Spaulding C, Dumonteil N, et al. Cost-effectiveness analysis of SAPIEN 3 TAVI procedure compared with surgery in patients with severe aortic stenosis at low risk of surgical mortality in France. Value Health. 2022;25:605\u201313.","journal-title":"Value Health."},{"key":"1012_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ijcard.2022.03.034","volume":"357","author":"FS Mennini","year":"2022","unstructured":"Mennini FS, Meucci F, Pesarini G, Vandoni P, Lettino M, Sarmah A, et al. Cost-effectiveness of transcatheter aortic valve implantation versus surgical aortic valve replacement in low surgical risk aortic stenosis patients. Int J Cardiol. 2022;357:26\u201332.","journal-title":"Int J Cardiol"},{"key":"1012_CR12","doi-asserted-by":"crossref","unstructured":"V\u00e1zquez Rodr\u00edguez JM, Berm\u00fadez EP, Zamorano JL, Burgos JM, D\u00edaz-Fern\u00e1ndez JF, del Blanco BG, et al. Cost-effectiveness of SAPIEN 3 transcatheter aortic valve implantation in low surgical mortality risk patients in Spain. REC Interv Cardiol. 2023:38\u201345.","DOI":"10.24875\/RECICE.M22000340"},{"key":"1012_CR13","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s12325-022-02392-y","volume":"40","author":"KH Kuck","year":"2023","unstructured":"Kuck KH, Leidl R, Frankenstein L, Wahlers T, Sarmah A, Candolfi P, et al. Cost-effectiveness of SAPIEN 3 transcatheter aortic valve implantation versus surgical aortic valve replacement in German severe aortic stenosis patients at low surgical mortality risk. Adv Ther. 2023;40:1031\u201346.","journal-title":"Adv Ther"},{"key":"1012_CR14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1080\/00015385.2023.2282283","volume":"79","author":"C Dubois","year":"2024","unstructured":"Dubois C, Adriaenssens T, Annemans L, Bosmans J, Callebaut B, Candolfi P, et al. Transcatheter aortic valve implantation versus surgical aortic valve replacement in severe aortic stenosis patients at low surgical mortality risk: a cost-effectiveness analysis in Belgium. Acta Cardiol. 2024;79:46\u201357.","journal-title":"Acta Cardiol"},{"key":"1012_CR15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12962-024-00531-6","volume":"22","author":"R Eerdekens","year":"2024","unstructured":"Eerdekens R, Kats S, Grutters JP, Green M, Shore J, Candolfi P, et al. Cost-utility analysis of TAVI compared with surgery in patients with severe aortic stenosis at low risk of surgical mortality in the Netherlands. Cost Eff Resour Alloc. 2024;22:24.","journal-title":"Cost Eff Resour Alloc"},{"key":"1012_CR16","doi-asserted-by":"publisher","DOI":"10.48101\/ujms.v129.10741","volume":"129","author":"K Nilsson","year":"2024","unstructured":"Nilsson K, James S, Anger\u00e5s O, Backes J, Bjursten H, Candolfi P, et al. Cost-effectiveness analysis of transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis at low risk of surgical mortality in Sweden. Ups J Med Sci. 2024;129:e10741.","journal-title":"Ups J Med Sci"},{"key":"1012_CR17","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.57187\/s.3558","volume":"154","author":"CA Wyss","year":"2024","unstructured":"Wyss CA, Corti R, Nestelberger T, Candolfi P, Delbaere A, Fischer B, et al. Transcatheter aortic valve implantation with SAPIEN 3 versus surgical aortic valve replacement in patients with symptomatic severe aortic stenosis at low risk of surgical mortality: a cost-utility analysis for Switzerland. Swiss Med Wkly. 2024;154:3558.","journal-title":"Swiss Med Wkly"},{"key":"1012_CR18","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2147\/CEOR.S392566","volume":"15","author":"L Heathcote","year":"2023","unstructured":"Heathcote L, Srivastava T, Sarmah A, Kearns B, Sutton A, Candolfi P. A systematic review and statistical analysis of factors influencing the cost-effectiveness of transcatheter aortic valve implantation for symptomatic severe aortic stenosis. Clinicoecon Outcomes Res. 2023;15:459\u201375.","journal-title":"Clinicoecon Outcomes Res."},{"key":"1012_CR19","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1056\/NEJMoa1814052","volume":"380","author":"MJ Mack","year":"2019","unstructured":"Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695\u2013705.","journal-title":"N Engl J Med"},{"key":"1012_CR20","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.jacc.2020.12.052","volume":"77","author":"MB Leon","year":"2021","unstructured":"Leon MB, Mack MJ, Hahn RT, Thourani VH, Makkar R, Kodali SK, et al. Outcomes 2 years after transcatheter aortic valve replacement in patients at low surgical risk. J Am Coll Cardiol. 2021;77:1149\u201361.","journal-title":"J Am Coll Cardiol"},{"key":"1012_CR21","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1056\/NEJMoa2307447","volume":"389","author":"MJ Mack","year":"2023","unstructured":"Mack MJ, Leon MB, Thourani VH, Pibarot P, Hahn RT, Genereux P, et al. Transcatheter aortic-valve replacement in low-risk patients at five years. N Engl J Med. 2023;389:1949\u201360.","journal-title":"N Engl J Med"},{"key":"1012_CR22","unstructured":"Hern\u00e1ndez Alava M, Pudney S, Wailoo A. Estimating EQ-5D by age and sex for the UK. Report by the Decision Support Unit. 2022. https:\/\/sheffield.ac.uk\/nice-dsu\/methods-development\/estimating-eq-5d. Accessed 1 Nov 2025."},{"key":"1012_CR23","unstructured":"Public Health England. Briefing document: first incidence of stroke. Estimates for England 2007 to 2016. February 2018. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/678444\/Stroke_incidence_briefing_document_2018.pdf. Accessed 1 Nov 2025."},{"key":"1012_CR24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12916-019-1350-5","volume":"17","author":"J Hewitt","year":"2019","unstructured":"Hewitt J, Pennington A, Smith A, Gething S, Price M, White J, et al. A multi-centre, UK-based, non-inferiority randomised controlled trial of 4 follow-up assessment methods in stroke survivors. BMC Med. 2019;17:111.","journal-title":"BMC Med"},{"key":"1012_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4482","volume":"354","author":"A Odutayo","year":"2016","unstructured":"Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ. 2016;354:i4482.","journal-title":"BMJ"},{"key":"1012_CR26","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.athoracsur.2014.09.030","volume":"99","author":"T Bourguignon","year":"2015","unstructured":"Bourguignon T, Bouquiaux-Stablo AL, Candolfi P, Mirza A, Loardi C, May MA, et al. Very long-term outcomes of the Carpentier-Edwards Perimount valve in aortic position. Ann Thorac Surg. 2015;99:831\u20137.","journal-title":"Ann Thorac Surg"},{"key":"1012_CR27","first-page":"E552","volume":"97","author":"A Myat","year":"2021","unstructured":"Myat A, Buckner L, Mouy F, Cockburn J, Baumbach A, Banning AP, et al. In-hospital stroke after transcatheter aortic valve implantation: a UK observational cohort analysis. Catheter Cardiovasc Interv. 2021;97:E552\u20139.","journal-title":"Catheter Cardiovasc Interv"},{"key":"1012_CR28","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1177\/0272989X11401031","volume":"31","author":"PW Sullivan","year":"2011","unstructured":"Sullivan PW, Slejko JF, Sculpher MJ, Ghushchyan V. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Mak. 2011;31:800\u20134.","journal-title":"Med Decis Mak"},{"key":"1012_CR29","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1212\/WNL.0b013e3182a9f45f","volume":"81","author":"R Luengo-Fernandez","year":"2013","unstructured":"Luengo-Fernandez R, Gray AM, Bull L, Welch S, Cuthbertson F, Rothwell PM. Quality of life after TIA and stroke: ten-year results of the Oxford Vascular Study. Neurology. 2013;81:1588\u201395.","journal-title":"Neurology"},{"key":"1012_CR30","unstructured":"NHS England. 2021\/22 National cost collection data publication. https:\/\/www.england.nhs.uk\/publication\/2021-22-national-cost-collection-data-publication\/. Accessed 1 Nov 2025."},{"key":"1012_CR31","unstructured":"Jones K, Weatherly H, Birch S, Castelli A, Chalkley M, Dargan A, et al. Unit costs of health and social care 2022. https:\/\/kar.kent.ac.uk\/100519\/1\/Unit%20Costs%20of%20health%20and%20Social%20Care%202022%20%28amended%2013%20July%202023%29.pdf. Accessed 1 Nov 2025."},{"key":"1012_CR32","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1136\/heartjnl-2011-300646","volume":"98","author":"AR Kansal","year":"2012","unstructured":"Kansal AR, Sorensen SV, Gani R, Obinson P, Pan F, Plumb JM, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart. 2012;98:573\u20138.","journal-title":"Heart"},{"key":"1012_CR33","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/2396987317746516","volume":"3","author":"XM Xu","year":"2018","unstructured":"Xu XM, Vestesson E, Paley L, Desikan A, Wonderling D, Hoffman A, et al. The economic burden of stroke care in England, Wales and Northern Ireland: using a national stroke register to estimate and report patient-level health economic outcomes in stroke. Eur Stroke J. 2018;3:82\u201391.","journal-title":"Eur Stroke J"},{"key":"1012_CR34","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1080\/13696998.2020.1854769","volume":"23","author":"J Shore","year":"2020","unstructured":"Shore J, Russell J, Frankenstein L, Candolfi P, Green M. An analysis of the cost-effectiveness of transcatheter mitral valve repair for people with secondary mitral valve regurgitation in the UK. J Med Econ. 2020;23:1425\u201334.","journal-title":"J Med Econ"},{"key":"1012_CR35","first-page":"556","volume":"7","author":"DY Tam","year":"2021","unstructured":"Tam DY, Azizi PM, Fremes SE, Chikwe J, Gaudino M, Wijeysundera HC. The cost-effectiveness of transcatheter aortic valve replacement in low surgical risk patients with severe aortic stenosis. Eur Heart J. 2021;7:556\u201363.","journal-title":"Eur Heart J"},{"key":"1012_CR36","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.hlc.2020.09.934","volume":"30","author":"JY Zhou","year":"2021","unstructured":"Zhou JY, Liew D, Duffy SJ, Walton A, Htun N, Stub D. Cost-effectiveness of transcatheter versus surgical aortic valve replacement in low-risk patients with severe aortic stenosis. Heart Lung Circ. 2021;30:547\u201354.","journal-title":"Heart Lung Circ"},{"key":"1012_CR37","doi-asserted-by":"publisher","first-page":"1204520","DOI":"10.3389\/fcvm.2023.1204520","volume":"10","author":"F Rumi","year":"2023","unstructured":"Rumi F, Fortunato A, Antonini D, Siviero L, Cicchetti A. Analysis of heterogeneity of the different health technology assessment reports produced on the transcatheter aortic valve implantation in patients with severe aortic valve stenosis at low surgical risk. Front Cardiovasc Med. 2023;10:1204520.","journal-title":"Front Cardiovasc Med"},{"key":"1012_CR38","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.hlpt.2020.09.006","volume":"10","author":"J Enzing","year":"2021","unstructured":"Enzing J, Vijgen S, Knies S, Boer B, Brouwer W. Do economic evaluations of TAVI deal with learning effects, innovation, and context dependency? A review. Health Policy Technol. 2021;10:111\u20139.","journal-title":"Health Policy Technol"},{"key":"1012_CR39","unstructured":"Norwegian Institute of Public Health (NIPH). Transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement (SAVR) for patients with severe aortic stenosis and low surgical risk and across surgical risk groups: a health technology assessment 2021. https:\/\/www.fhi.no\/en\/publ\/2021\/TAVI-vs-SAVR-for-patients-with-severe-aortic-stenosis-and-low-surgical-risk-and-across-surgical-risk-groups\/. Accessed 1 Nov 2025."},{"key":"1012_CR40","unstructured":"Health Information and Quality Authority (HIQA). Health Technology Assessment of transcatheter aortic valve implantation (TAVI) in patients with severe symptomatic aortic stenosis at low and intermediate risk of surgical complications 2019. https:\/\/www.hiqa.ie\/sites\/default\/files\/2019-12\/TAVI_HTA.pdf. Accessed 1 Nov 2025."},{"key":"1012_CR41","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1161\/CIRCULATIONAHA.122.062481","volume":"147","author":"BZ Galper","year":"2023","unstructured":"Galper BZ, Chinnakondepalli KM, Wang K, Magnuson EA, Lu M, Thourani VH, et al. Economic outcomes of transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis and low surgical risk: results from the PARTNER 3 trial. Circulation. 2023;147:1594\u2013605.","journal-title":"Circulation"},{"key":"1012_CR42","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/13696998.2024.2346397","volume":"27","author":"J Kobayashi","year":"2024","unstructured":"Kobayashi J, Baron SJ, Takagi K, Thompson CA, Jiao X, Yamabe K. Cost-effectiveness analysis of transcatheter aortic valve implantation in aortic stenosis patients at low- and intermediate-surgical risk in Japan. J Med Econ. 2024;27:697\u2013707.","journal-title":"J Med Econ"},{"key":"1012_CR43","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006."},{"issue":"5","key":"1012_CR44","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jcin.2022.01.279","volume":"15","author":"MR Williams","year":"2022","unstructured":"Williams MR, Jilaihawi H, Makkar R, O\u2019Neill WW, Guyton R, Malaisrie SC, et al. The PARTNER 3 bicuspid registry for transcatheter aortic valve replacement in low-surgical-risk patients. JACC Cardiovasc Interv. 2022;15(5):523\u201332.","journal-title":"JACC Cardiovasc Interv"},{"issue":"37","key":"1012_CR45","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.1093\/eurheartj\/ehae331","volume":"45","author":"TH J\u00f8rgensen","year":"2024","unstructured":"J\u00f8rgensen TH, Thyregod HGH, Savontaus M, Willemen Y, Bleie \u00d8, Tang M, et al. Transcatheter aortic valve implantation in low-risk tricuspid or bicuspid aortic stenosis: the NOTION-2 trial. Eur Heart J. 2024;45(37):3804\u201314.","journal-title":"Eur Heart J"},{"issue":"7","key":"1012_CR46","first-page":"1258","volume":"41","author":"TT Lerman","year":"2025","unstructured":"Lerman TT, Greenberg N, Kheifets M, Talmor-Barkan Y, Codner P, Perl L, et al. Transcatheter aortic valve implantation vs surgical aortic valve replacement in patients at lower surgical risk: meta-analysis of randomized trials. Can J Cardiol. 2025;41(7):1258\u201369.","journal-title":"Can J Cardiol"},{"key":"1012_CR47","unstructured":"NHS England. Transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) for symptomatic, severe aortic stenosis (adults) to support elective performance. 2023. https:\/\/www.england.nhs.uk\/long-read\/tavi-and-savr-position-statement\/#:~:text=ii)%20Risk%20scores%20such%20as,approach%20determined%20by%20MDM%20assessment. Accessed 1 Nov 2025."}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-025-01012-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-025-01012-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-025-01012-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T13:15:34Z","timestamp":1771679734000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40258-025-01012-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1012"],"URL":"https:\/\/doi.org\/10.1007\/s40258-025-01012-4","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"25 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nick Curzen received research grants from Boston, HeartFlow, Haemonetics and Beckman Coulter; speaker fees\/consultancy from Abbott, HeartFlow, Shockwave and Boston; and travel sponsorship from HeartFlow, Biosensors and Shockwave. Pascal Candolfi is an employee at Edwards Lifesciences, Nyon, Switzerland. Philip MacCarthy has no conflicts of interest that are directly relevant to the content of this article. Clinton T. Lloyd has been a speaker for Edwards Lifesciences. Muhammad Aetesam-Ur-Rahman has been a consultant and received speaker fees from Medtronic and SMT. Tom Bromilow has been a consultant for Edwards Lifesciences. Valentina Sellitto is an employee at Edwards Lifesciences, Milan, Italy. Daniel J. Blackman received an institutional research grant from Medtronic and is a consultant and speaker for Medtronic, Abbott Vascular, JenaValve and Edwards Lifesciences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Input parameters values used and data generated during this cost-utility study are wholly included within this article and the associated Electronic Supplementary Material.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Input parameters values used and data generated during this cost-utility study are wholly included within this article and the associated Electronic Supplementary Material. The code was only used in the model to run a probabilistic and deterministic sensitivity analysis and so will not be made available.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"PC led the project and contributed to the methodology, data analysis and manuscript drafting, and serves as the guarantor, ensuring the integrity and accuracy of the work. VS assisted with model adaptation and manuscript drafting. TB adapted the model, ensured the use of the best methodology and provided a health economics opinion. PMC, DB, CL, MAR and NC provided expert clinical opinion and economic guidance, contributing to the interpretation of results and critical review of the manuscript. All authors reviewed and approved the final version.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}